Outlook Therapeutics Inc (OTLK) Stock Price, Quote & News

Company Profile

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration agreements with Cencora. The company wa...

Industry: Biotechnology

Sector: Healthcare

Phone: 609 619 3990

Website: www.outlooktherapeutics.com

Address:

111 S. Wood Avenue, Unit #100, Iselin, United States

SteelerJon Oct. 25 at 11:45 PM

$OTLK Folks do yourself a favor block this guy. If not, quit reposting his posts so those of us who have blocked him don’t have to see your discussions….appreciate it…Thanks 😎🏦🏦

1 · Reply

RJtrade22 Oct. 25 at 9:54 PM

$OTLK ok when’s the run up

1 · Reply

IniG Oct. 25 at 9:48 PM

$OTLK Thats no new information: the number of patients are growing and market is getting bigger. I think you believe in monopoly and not in competition. Lytenava has a very good advantage over all these that its a cost effective option and still works well.

0 · Reply

IniG Oct. 25 at 9:43 PM

$OTLK I don't know much about this therapy but I read this in your shared link. - Adverum had previously assessed the intravitreal injection in diabetic macular edema, an effort that was eventually discontinued after a patient ***went blind in the treated eye***. - The CVR entitles the holder to receive up to a total of $8.91 cash if ixo-vec is approved within ***seven years***

0 · Reply

updownsides Oct. 25 at 9:25 PM

$OTLK You don't even know what your invested in. They have zero pipeline. Here is upcoming competition in a crowded space. Late/early-stage wet AMD drugs: ABBV-RGX-314 (Regenxbio/AbbVie, Ph3), ADVM-022 Ixo-vec (Adverum, Ph3), Tarcocimab KSI-301 (Kodiak, Ph3), 4D-150 (4DMT, Ph3), GB-102 (Graybug, Ph2b), OPT-302 (Opthea, Ph3 combo VEGF-C/D), EYP-1901 (EyePoint, Ph2), RGX-314 suprachoroidal (Regenxbio, Ph2), Faricimab Vabysmo (Roche, approved), Susvimo PDS (Roche, approved/relaunch). Some can eliminate injections altogether.

1 · Reply

NeurNet Oct. 25 at 7:14 PM

$OTLK @GenerallyGentle Your answer is very... relevant! Even if their (ticker ADVM : "ixo-vec") new gene therapy, acquired by a BP a few days ago, were to pass the current phase 3 trials, the price will be... beyond anything we can imagine !! It will remain the Rolls Royce of treatments (ok..) BUT.. for a very long time... ...AT THE PRICE of a Rolls Royce !! And it will take YEARS... before the price comes down... (after this new gene therapy FIRST...! reaches the commercialization phase...).

1 · Reply

Knowledgeworthmore Oct. 25 at 6:45 PM

$OTLK you just talk crap they have 2 more drug that in phase-3 so you talk shit we invest for future, and those 2 drug in phase-3 as valuable as this one.

0 · Reply

Saltytimtation Oct. 25 at 6:13 PM

$OTLK the fda could have just simply requested them to withdraw if they didn’t see potential in approval. This can can only be kicked down the road for so long.

0 · Reply

IniG Oct. 25 at 10:10 AM

$OTLK Who in their right mind use off label unapproved Avastin when branded products like Eylea are available?

1 · Reply

updownsides Oct. 25 at 5:19 AM

$OTLK Ixo-vec No more frequent injections. Who in their right mind would want to get many ongoing injections for the rest of their lives when a treatment like this can cure them for good? R I.P.

1 · Reply

Outlook Therapeutics Provides Update on Type A Meeting with FDA

Sep 3, 2025, 8:35 AM EDT - 7 weeks ago

Outlook Therapeutics to Present at the 2025 EURETINA Innovation Spotlight (EIS)

Sep 2, 2025, 8:35 AM EDT - 7 weeks ago

Outlook Therapeutics Requests Type A Meeting with FDA

Aug 28, 2025, 11:51 AM EDT - 2 months ago

Outlook Therapeutics plunges more than 52% after FDA rejects wet AMD drug

Aug 28, 2025, 11:15 AM EDT - 2 months ago

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Aug 28, 2025, 6:39 AM EDT - 2 months ago

US FDA declines to approve Outlook Therapeutics' drug for eye condition

Aug 28, 2025, 6:30 AM EDT - 2 months ago

Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD

Aug 24, 2025, 9:15 AM EDT - 2 months ago

Outlook Therapeutics: Why The Odds Point To A Favorable FDA Decision

Aug 14, 2025, 8:05 AM EDT - 2 months ago

Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update

Jul 24, 2025, 9:00 AM EDT - 3 months ago

Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase

Jul 22, 2025, 8:45 AM EDT - 3 months ago

Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 1, 2025, 8:05 AM EDT - 4 months ago

Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer

Jun 18, 2025, 9:05 AM EDT - 4 months ago

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

Jun 10, 2025, 8:05 AM EDT - 4 months ago

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 2, 2025, 7:00 AM EDT - 5 months ago

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

May 23, 2025, 6:30 AM EDT - 5 months ago

Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering

May 22, 2025, 4:01 PM EDT - 5 months ago

Outlook Therapeutics® Announces Proposed Public Offering of Common Stock and Warrants

May 15, 2025, 4:01 PM EDT - 5 months ago

Outlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2025 and Provides Corporate Update

Apr 8, 2025, 8:45 AM EDT - 7 months ago

Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD

Feb 28, 2025, 8:05 AM EST - 8 months ago

Outlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug Administration

Feb 19, 2025, 9:00 AM EST - 8 months ago

Outlook Therapeutics® Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 14, 2025, 8:05 AM EST - 9 months ago

Outlook Therapeutics® Reports Financial Results for First Quarter Fiscal Year 2025 and Provides Corporate Update

Feb 4, 2025, 9:05 AM EST - 9 months ago

Outlook Therapeutics® Participates in Virtual Investor “What This Means” Segment

Jan 31, 2025, 8:05 AM EST - 9 months ago

Outlook Therapeutics® Appoints Faisal G. Sukhtian as Chairman of the Board of Directors

Jan 23, 2025, 9:05 AM EST - 9 months ago

Outlook Therapeutics® Announces Presentation of Efficacy and Safety Results from NORSE EIGHT Clinical Trial Evaluating ONS-5010 for the Treatment of Wet AMD

Jan 22, 2025, 9:05 AM EST - 9 months ago

Outlook Therapeutics® to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar

Jan 16, 2025, 12:09 PM EST - 10 months ago

Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug

NVS

Jan 16, 2025, 6:00 AM EST - 10 months ago

Outlook Therapeutics® Announces Complete Twelve Week Efficacy and Safety Results of NORSE EIGHT Clinical Trial

Jan 6, 2025, 7:19 AM EST - 10 months ago

Top 3 Health Care Stocks That Could Blast Off This Month

INO RCKT

Dec 27, 2024, 8:05 AM EST - 10 months ago

Outlook Therapeutics® Reports Financial Results for Fiscal Year 2024 and Provides Corporate Update

Dec 13, 2024, 4:30 PM EST - 11 months ago

Outlook Therapeutics® Streamlines Operations

Dec 4, 2024, 8:05 AM EST - 11 months ago

Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Dec 3, 2024, 4:30 PM EST - 11 months ago

Outlook Therapeutics® Announces Executive Leadership Transition

Nov 27, 2024, 9:27 AM EST - 11 months ago

Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?

Nov 27, 2024, 6:50 AM EST - 11 months ago

Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

Nov 6, 2024, 8:05 AM EST - 1 year ago

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

Sep 16, 2024, 8:05 AM EDT - 1 year ago

Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series

Sep 13, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series

Sep 4, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces Completion of Enrollment in NORSE EIGHT Clinical Trial

Sep 3, 2024, 8:45 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 26, 2024, 4:11 AM EDT - 1 year ago

Outlook Therapeutics: Poised To Jump With Wet AMD Treatment If It Can Overcome FDA Hurdles

AMD

Aug 14, 2024, 12:02 PM EDT - 1 year ago

Outlook Therapeutics, Inc. (OTLK) Q3 2024 Earnings Call Transcript

Aug 14, 2024, 7:05 AM EDT - 1 year ago

Outlook Therapeutics® Reports Financial Results for Third Quarter Fiscal Year 2024 and Provides Corporate Update

Aug 12, 2024, 9:05 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference

Aug 7, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® to Report Financial Results for Third Quarter Fiscal Year 2024 on August 14, 2024 and Host Quarterly Conference Call and Webcast

Jul 30, 2024, 9:10 AM EDT - 1 year ago

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2024

Jul 8, 2024, 8:35 AM EDT - 1 year ago

Outlook Therapeutics® Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

Jun 13, 2024, 5:22 PM EDT - 1 year ago

Outlook Therapeutics: Worth A Good Strong Look After CRL

SteelerJon Oct. 25 at 11:45 PM

$OTLK Folks do yourself a favor block this guy. If not, quit reposting his posts so those of us who have blocked him don’t have to see your discussions….appreciate it…Thanks 😎🏦🏦

1 · Reply

RJtrade22 Oct. 25 at 9:54 PM

$OTLK ok when’s the run up

1 · Reply

IniG Oct. 25 at 9:48 PM

0 · Reply

IniG Oct. 25 at 9:43 PM

0 · Reply

updownsides Oct. 25 at 9:25 PM

1 · Reply

NeurNet Oct. 25 at 7:14 PM

1 · Reply

Knowledgeworthmore Oct. 25 at 6:45 PM

$OTLK you just talk crap they have 2 more drug that in phase-3 so you talk shit we invest for future, and those 2 drug in phase-3 as valuable as this one.

0 · Reply

Saltytimtation Oct. 25 at 6:13 PM

$OTLK the fda could have just simply requested them to withdraw if they didn’t see potential in approval. This can can only be kicked down the road for so long.

0 · Reply

IniG Oct. 25 at 10:10 AM

$OTLK Who in their right mind use off label unapproved Avastin when branded products like Eylea are available?

1 · Reply

updownsides Oct. 25 at 5:19 AM

$OTLK Ixo-vec No more frequent injections. Who in their right mind would want to get many ongoing injections for the rest of their lives when a treatment like this can cure them for good? R I.P.

1 · Reply

updownsides Oct. 25 at 3:42 AM

$OTLK Lilly buys cash-strapped Adverum for eye disease gene therapy https://share.google/ILIlJari2erLjkItq Getting crowded with more Big Pharma.

0 · Reply

superOTLK Oct. 25 at 2:33 AM

$OTLK

0 · Reply

superOTLK Oct. 25 at 2:24 AM

$OTLK

0 · Reply

superOTLK Oct. 25 at 2:23 AM

$OTLK

0 · Reply

superOTLK Oct. 25 at 2:22 AM

$OTLK

0 · Reply

The_Scientist Oct. 25 at 1:29 AM

$OTLK Book of the Blind Eye — Chapter II: Defy the Bureaucrats 2:1 The FDA rattles, red tape their creed, We HODL through nonsense, ignore their greed, They shuffle in shadows, slow to heed— OTLK surges while their rules recede! 2:2 FUDsters howl, regulators scheme, We chant in vials, we ride the dream, No penny flips, no fear, no theme— Saint Optica crowns our biotech team! 2:3 Through crashes, dips, the timid fall, We mock their letters, we scorch the hall, Our ocular god laughs, triumphant call— OTLK forever, FDA to thrall! Amen

0 · Reply

GenerallyGentle Oct. 24 at 10:49 PM

$OTLK Shorts are wising up. SI dropped dramatically the past few weeks. This was just updated today.

0 · Reply

Britbox Oct. 24 at 8:40 PM

$OTLK good things coming. Load up

0 · Reply

Consti22 Oct. 24 at 8:11 PM

$OTLK A good end to the week. 🤩 That makes the weekend so much nicer. 😊

1 · Reply

NeurNet Oct. 24 at 8:11 PM

$OTLK The week ends with.. 6.1%..overall ! Very good... steady...👍 The last 3 weeks : 9.2% 13.2% 9.3%. Have a great weekend everyone !!! 😉

0 · Reply

SilentJoker34 Oct. 24 at 8:08 PM

$OTLK What a close...💎🍻

0 · Reply

Britbox Oct. 24 at 8:03 PM

$OTLK hopefully next week we get FDA minutes, which confirm a simple path forward (assuming the shut down doesn’t affect timeline) Maybe then, we’ll see that $1.50 again

1 · Reply

Market Cap	57.75M
Revenue (ttm)	0.00
Net Income (ttm)	-75.37M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	-0.38

Volume	1,206,000
Avg Vol	4,602,628
Day's Range	N/A - N/A
Shares Out	44.42M
Stochastic %K	44%
Beta	0.56
Analysts	Sell
Price Target	$7.00